{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:27:11Z","timestamp":1789673231017,"version":"4.0.1"},"reference-count":98,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:53:18Z","timestamp":1757083998000},"page":"545-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autoantibodies in Myositis"],"prefix":"10.1016","volume":"51","author":[{"given":"Eugene","family":"Krustev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Christopher-Stine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib1","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.002_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101767","article-title":"Autoantibodies: pathogenic or epiphenomenon","volume":"36","author":"Galindo-Feria","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.002_bib5","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/art.41762","article-title":"Expert perspective: management of refractory inflammatory myopathy","volume":"73","author":"Lundberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.41088","article-title":"Myositis autoantibodies: a comparison of results from the Oklahoma medical research foundation myositis panel to the euroimmun research line blot","volume":"72","author":"Mecoli","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000001039","article-title":"Autoantibody testing in myositis: an update","volume":"36","author":"McMorrow","year":"2024","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib9","first-page":"128","article-title":"The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum","volume":"31","author":"Ghazi","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine"},{"issue":"19","key":"10.1016\/j.rdc.2025.07.002_bib11","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1684\/ejd.2020.3750","article-title":"Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","volume":"30","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib13","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.002_bib14","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/acr.23188","article-title":"Dermatomyositis patients with anti-nuclear matrix protein-2 autoantibodies have more edema, more severe muscle disease, and increased malignancy risk","volume":"69","author":"Albayda","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003901","article-title":"Severe gastrointestinal involvements in patients with adult dermatomyositis with anti-NXP2 antibody","volume":"10","author":"Fu","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib16","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.47102\/annals-acadmedsg.2022278","article-title":"Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore","volume":"51","author":"Chua","year":"2022","journal-title":"Ann Acad Med Singapore"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103464","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review","volume":"22","author":"Kilinc","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib19","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/ard-2022-222441","article-title":"Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1\u03b3 autoantibodies","volume":"82","author":"Hosono","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150201","article-title":"Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence","volume":"132","author":"Fiorentino","year":"2022","journal-title":"J Clin Investig"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib21","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) Antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.002_bib22","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1093\/rheumatology\/kead065","article-title":"Bullous periorbital oedema in anti-p155\/140-positive dermatomyositis: a case series","volume":"62","author":"Connolly","year":"2023","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.chest.2020.04.057","article-title":"Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR Model","volume":"158","author":"Lian","year":"2020","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.14999","article-title":"Aggressive multi-combination therapy for anti-MDA5 antibody-positive dermatomyositis-rapidly progressive interstitial lung disease","volume":"27","author":"Hata","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib27","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/acr2.11247","article-title":"A North American cohort of anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases","volume":"3","author":"Albayda","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41598-017-00240-6","article-title":"Clinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts","volume":"7","author":"Ge","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.rdc.2025.07.002_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.104453","article-title":"273rd ENMC international workshop: clinico-sero-morphological classification of the antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023","volume":"45","author":"Stenzel","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"32","key":"10.1016\/j.rdc.2025.07.002_bib33","article-title":"Clinical spectrum time course in anti jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (United States)"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib34","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1002\/art.22865","article-title":"Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy","volume":"56","author":"Stone","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib35","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.002_bib39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/acr.22620","article-title":"Spectrum of muscle histopathologic findings in forty-two scleroderma patients with weakness","volume":"67","author":"Paik","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000635","article-title":"Clinical and histopathological features of myositis in systemic lupus erythematosus","volume":"9","author":"Tiniakou","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.002_bib41","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib43","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib45","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/cns.13658","article-title":"Juvenile idiopathic inflammatory myopathies with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in a Chinese cohort","volume":"27","author":"Hou","year":"2021","journal-title":"CNS Neurosci Ther"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib46","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3899\/jrheum.160871","article-title":"Anti-HMGCR autoantibodies in juvenile idiopathic inflammatory myopathies identify a rare but clinically important subset of patients","volume":"44","author":"Tansley","year":"2017","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103468","article-title":"Anti-HMGCR immune-mediated necrotising myopathy: addressing the remaining issues","volume":"22","author":"Khoo","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"29","key":"10.1016\/j.rdc.2025.07.002_bib49","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.3748\/wjg.v16.i29.3616","article-title":"Primary biliary cirrhosis: what do autoantibodies tell us?","volume":"16","author":"Hu","year":"2010","journal-title":"World J Gastroenterol : WJG"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib50","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0002-9343(72)90064-2","article-title":"Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA)","volume":"52","author":"Sharp","year":"1972","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.002_bib51","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/00002281-199911000-00004","article-title":"Myositis overlap syndromes","volume":"6","author":"Ioannou","year":"1999","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","article-title":"2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"issue":"13","key":"10.1016\/j.rdc.2025.07.002_bib53","doi-asserted-by":"crossref","first-page":"E1416","DOI":"10.1212\/WNL.0000000000007188","article-title":"Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies","volume":"92","author":"Casal-Dominguez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2025.07.002_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103220","article-title":"Anti-U1RNP antibodies are associated with a distinct clinical phenotype and a worse survival in patients with systemic sclerosis","volume":"146","author":"Chevalier","year":"2024","journal-title":"J Autoimmun"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1525-1470.1991.tb00830.x","article-title":"Childhood scleromyositis: an overlap syndrome associated with PM-Scl Antibody","volume":"8","author":"Bfaszczyk","year":"1991","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.rdc.2025.07.002_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152536","article-title":"Clinical characteristics of idiopathic inflammatory myopathies patients with anti-PM\/Scl antibodies","volume":"68","author":"Zhu","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.002_bib57","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1093\/rheumatology\/keab152","article-title":"The clinical phenotype of systemic sclerosis patients with anti-PM\/Scl antibodies: results from the EUSTAR cohort","volume":"60","author":"Lazzaroni","year":"2021","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003081","article-title":"In inflammatory myopathies, dropped head\/bent spine syndrome is associated with scleromyositis: an international case\u2013control study","volume":"9","author":"Pijnenburg","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2025.07.002_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.974078","article-title":"Scleromyositis: a distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis","volume":"13","author":"Giannini","year":"2023","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib61","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1177\/09612033221122158","article-title":"Serologic phenotypes distinguish systemic lupus erythematosus patients developing interstitial lung disease and\/or myositis","volume":"31","author":"Cotton","year":"2022","journal-title":"Lupus"},{"issue":"SUPPL.76","key":"10.1016\/j.rdc.2025.07.002_bib62","article-title":"A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodie","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"35","key":"10.1016\/j.rdc.2025.07.002_bib63","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine (United States)"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.002_bib64","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib65","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1093\/rheumatology\/keae199","article-title":"Increased risk of myocarditis and arrythmias in anti-Ku-positive scleroderma\u2013myositis overlap patients: a case series","volume":"63","author":"Bhalodia","year":"2024","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib66","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1084\/jem.167.5.1560","article-title":"A 52-kD protein is a novel component of the SS-A\/Ro antigenic particle","volume":"167","author":"Ben-Chetrit","year":"1988","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib68","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.autrev.2009.02.010","article-title":"Latest update on the Ro\/SS-A autoantibody system","volume":"8","author":"Schulte-Pelkum","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.002_bib69","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib70","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib71","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib72","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM195801232580407","article-title":"Primary biliary cirrhosis showing a high titer of autoantibody","volume":"258","author":"Mackay","year":"1958","journal-title":"N Engl J Med"},{"issue":"7390","key":"10.1016\/j.rdc.2025.07.002_bib73","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(65)91372-3","article-title":"Serological tests in diagnosis of primary biliary cirrhosis","volume":"285","author":"Walker","year":"1965","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib74","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.semarthrit.2017.06.004","article-title":"Inflammatory myopathy associated with anti-mitochondrial antibodies: a distinct phenotype with cardiac involvement","volume":"47","author":"Albayda","year":"2018","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib75","first-page":"68","article-title":"High prevalence of anti-mitochondrial antibodies among patients with some well-defined connective tissue diseases","volume":"66","author":"Mouritsen","year":"1986","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib76","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1093\/brain\/aws106","article-title":"Inflammatory myopathies associated with anti-mitochondrial antibodies","volume":"135","author":"Maeda","year":"2012","journal-title":"Brain"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.002_bib77","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1007\/s10067-021-05730-7","article-title":"Anti-mitochondrial autoantibodies are associated with cardiomyopathy, dysphagia, and features of more severe disease in adult-onset myositis","volume":"40","author":"Sabbagh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.002_bib78","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2024.03.001","article-title":"272nd ENMC international workshop: 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16\u201318 June 2023, Hoofddorp, The Netherlands","volume":"37","author":"Lilleker","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib79","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/BOR.0000000000000436","article-title":"Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment","volume":"29","author":"Schmidt","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib81","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib82","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/mus.27841","article-title":"Myositis-related autoantibody profile and clinical characteristics stratified by anti-cytosolic 5\u2032-nucleotidase 1A status in connective tissue diseases","volume":"68","author":"Diederichsen","year":"2023","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib83","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib84","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/kez406","article-title":"Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis","volume":"59","author":"Betteridge","year":"2020","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib85","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib86","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1093\/rheumatology\/kes102","article-title":"Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis","volume":"51","author":"Gono","year":"2012","journal-title":"Rheumatology"},{"issue":"Suppl 3","key":"10.1016\/j.rdc.2025.07.002_bib87","first-page":"A943.2","article-title":"AB0506 Longitudinal change of the titer of anti-mda5 antibody and association with prognosis in dermatomyositis with interstitial pneumonia","volume":"72","author":"Nakashima","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.002_bib88","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/rheumatology\/ker408","article-title":"Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM\/interstitial lung disease during disease remission","volume":"51","author":"Muro","year":"2012","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.002_bib89","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1093\/rheumatology\/kex188","article-title":"Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis","volume":"56","author":"Abe","year":"2017","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib90","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/rheumatology\/keac627","article-title":"Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis","volume":"62","author":"Kogami","year":"2023","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib91","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/rheumatology\/keu436","article-title":"Anti-signal recognition particle autoantibody ELISA validation and clinical associations","volume":"54","author":"Aggarwal","year":"2015","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib92","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.002_bib93","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.002_bib94","first-page":"150","article-title":"Anti-HMGCR autoantibodies in european patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (United States)"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.002_bib95","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/jdv.14754","article-title":"Four cases of anti-Mi-2 antibody-positive dermatomyositis: relationship between anti-Mi-2 antibody titre and disease severity and activity","volume":"32","author":"Matsuda","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.002_bib96","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1093\/rheumatology\/kead550","article-title":"Correlation between B-cell epitope profile and clinical features of anti-MDA5 antibody-positive dermatomyositis","volume":"63","author":"Yamaguchi","year":"2024","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-024-03387-6","article-title":"Association of anti-HMGCR antibodies of the IgM isotype with refractory immune-mediated necrotizing myopathy","volume":"26","author":"Yang","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.002_bib98","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/mus.24199","article-title":"Cytoplasmic 5\u2032-nucleotidase autoantibodies in inclusion body myositis: isotypes and diagnostic utility","volume":"50","author":"Greenberg","year":"2014","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.002_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-022-02745-6","article-title":"Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome","volume":"24","author":"Notarnicola","year":"2022","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:21:34Z","timestamp":1761592894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":98,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000493"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.002","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoantibodies in Myositis","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}